SenoRx, Inc. has just announced that the company has further extended its international reach to include five additional global markets. According a new announcement from SenoRx, the company will add to the 24 countries where SenoRx products are already being sold, through marketing of EnCor(r), its vacuum-assisted breast biopsy product, and its GelMark(tm) line of breast biopsy tissue markers via distributors in Egypt, Greece, Poland, Saudi Arabia, Thailand, Turkey and the United Arab Emirates. SenoRx develops, manufactures and sells minimally invasive medical devices for the diagnosis and treatment of breast cancer.

The press release says SenoRx is partnering with local in-country distributors who have "breast imaging and/or interventional radiology franchises in select markets." SenoRx says it has previously established partnering relationships with distributors in Australia, Austria, Belgium, Denmark, Finland, France, Germany, Hong Kong, Iceland, Ireland, Italy, Luxembourg, Mexico, The Netherlands, Norway, Portugal, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan and the United Kingdom.

"SenoRx continues to expand its international footprint in key markets where breast-care is increasingly becoming a national health care priority," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "We have had positive results with our earlier international expansion initiatives and continue to see attractive opportunities for growth in the global marketplace. With the addition of these seven new geographic markets, SenoRx will now have a presence in more than 30 countries outside North America."

EnCor and SenoRx breast tissue biopsy markers have already received the necessary regulatory clearances in countries within the European Economic Community as well as the other countries in which SenoRx has established distribution channels.

Adapted from a press release from SenoRX.

More HCB News